Revolution Medicines, Inc. Increase (Decrease) in Accounts Receivable, Related Parties
Revolution Medicines, Inc. (RVMD) reported Increase (Decrease) in Accounts Receivable, Related Parties of -$2.34 million for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-02.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties · last filed 2021-03-02
- Revolution Medicines, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2020-12-31 was -$2.91M.
- Revolution Medicines, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2020-09-30 was $1.97M, a 2975.00% increase year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2020-06-30 was -$1.12M, a 217.30% decline year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accounts receivable, related parties for the quarter ending 2020-03-31 was -$287.00K, a 145.63% decline year-over-year.
- Revolution Medicines, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2020 was -$2.34M, a 263.46% decline from fiscal 2019.
- Revolution Medicines, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2019 was $1.43M, a 80.36% decline from fiscal 2018.
- Revolution Medicines, Inc. increase (decrease) in accounts receivable, related parties for fiscal 2018 was $7.30M.
| Period end | Increase (Decrease) in Accounts Receivable, Related Parties 3 month | Increase (Decrease) in Accounts Receivable, Related Parties 6 month | Increase (Decrease) in Accounts Receivable, Related Parties 9 month | Increase (Decrease) in Accounts Receivable, Related Parties 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$2.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | -$938.00K derived: sum of 2 quarters · filed 2021-03-02 | -$2.06M derived: sum of 3 quarters · filed 2021-03-02 | -$2.34M 10-K · filed 2021-03-02 |
| 2020-09-30 | $1.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $849.00K derived: sum of 2 quarters · filed 2020-11-12 | $562.00K 10-Q · filed 2020-11-12 | $349.00K derived: sum of 4 quarters · filed 2021-03-02 |
| 2020-06-30 | -$1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | -$1.41M 10-Q · filed 2020-08-10 | -$1.62M derived: sum of 3 quarters · filed 2021-03-02 | -$1.55M derived: sum of 4 quarters · filed 2021-03-02 |
| 2020-03-31 | -$287.00K 10-Q · filed 2020-05-14 | -$500.00K derived: sum of 2 quarters · filed 2021-03-02 | -$436.00K derived: sum of 3 quarters · filed 2021-03-02 | $518.00K derived: sum of 4 quarters · filed 2021-03-02 |
| 2019-12-31 | -$213.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-02 | -$149.00K derived: sum of 2 quarters · filed 2021-03-02 | $805.00K derived: sum of 3 quarters · filed 2021-03-02 | $1.43M 10-K · filed 2021-03-02 |
| 2019-09-30 | $64.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.02M derived: sum of 2 quarters · filed 2020-11-12 | $1.65M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $954.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-10 | $1.58M 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | $629.00K 10-Q · filed 2020-05-14 | |||
| 2018-12-31 | $7.30M 10-K · filed 2021-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |